Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
23 November 2023 - 5:02PM
Novo Nordisk invests more than 16 billion Danish kroner in
expansion of production facilities in Chartres, France
Bagsværd, Denmark, 23 November 2023 – Novo
Nordisk today announced the investment of more than 16 billion
Danish kroner (2.1 billion euros) starting in 20231 to expand the
existing production site in Chartres, France, for the current and
future product portfolio within serious chronic diseases.
The investment will significantly increase the capacity of the
manufacturing site, adding aseptic production and finished
production processes and an extension of the current Quality
Control Laboratory. The investment, which includes capacity for
GLP-1 products, will increase Novo Nordisk’s ability to meet future
demands for innovative medicines.
“This significant investment announced today confirms the
importance of our French manufacturing site, one of our strategic
production sites, as a cornerstone of the growth we are
experiencing as a company. By maximising the skills and
infrastructure we already have on the site, we are expanding our
capacity in an efficient way”, said Lone Charlotte Larsen,
corporate vice president of Novo Nordisk Production Chartres.
The new facilities will more than double the footprint of the
site. The facility will be designed as a multi-product facility to
accommodate current and future processes and displaying
state-of-the-art technology and working environment. As a
future-proof and cost-effective facility, the construction will
focus on delivering the highest quality to patients globally in an
efficient and environmentally sustainable way2.
“Our continued investments in our manufacturing sites across the
globe demonstrate the belief we have in our current and future
product portfolio and its relevance for people living with serious
chronic diseases,” said Henrik Wulff, executive vice president,
Product Supply, Quality & IT, Novo Nordisk.
The construction projects have now been initiated and will
gradually be finalised from 2026 to 2028. The investment is
expected to create more than 500 new jobs to run production
activities 24/7 when the construction is completed, and the
facilities are finalised. During the construction phase, up to
2,000 external employees will be employed.
About Novo Nordisk manufacturing in Chartres
Novo Nordisk’s production facility in Chartres was established in
1961, and today the site employs around 1,600 people. The
production facility manufactures high quality treatments to 10
million people with diabetes all over the world who use "Made in
Chartres" therapeutic solutions every day.
About Novo Nordisk manufacturing Novo Nordisk
has a global manufacturing setup with five strategic production
sites located in Denmark, US, France, Brazil and China. All Novo
Nordisk’s medicines are manufactured at these sites and
subsequently distributed to patients around the globe. This
includes producing almost half of the world’s insulin, GLP-1
medicines for the treatment of diabetes and obesity and medicines
to treat rare diseases such as haemophilia and growth disorders.
Novo Nordisk’s manufacturing unit has almost 20,000 employees who
are dedicated to delivering the highest quality to patients
globally in an efficient and environmentally sustainable way.
About Novo Nordisk Novo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic
diseases, built upon our heritage in diabetes. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 61,400 people in 80 countries and markets its
products in around 170 countries. For more information, visit
novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Anne
Margrethe Hauge +45 3079
3450globalmedia@novonordisk.com |
|
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter+45 3075 8259fptr@novonordisk.com |
References
- A portion of this investment is
included in the DKK 25 billion capital expenditure announced in
connection with Novo Nordisk full year results in February 2023.
The additional amount will be invested through the next 4
years.
- The new facilities will reduce water
consumption by 25% compared to current production lines.
- PR231123-Chartres-investment
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024